Aiforia Technologies Plc: Comparative information on transition to IFRS reporting

Aiforia Technologies Plc Company release February 15, 2024 9:30 a.m. EET

On 1 December 2023, Aiforia Technologies Plc (‘Aiforia‘or ‘the company’) announced that it will switch from the Finnish Accounting Standards (FAS) to International Financial Reporting Standards (IFRS). Aiforia will prepare its consolidated financial statements and financial statements release for the financial year that ended on 31 December 2023 in accordance with IFRS, including comparative information under IFRS for the financial year 2022. The date of transition to IFRS was 1 January 2022. The financial statements release will be published on 7 March 2024 and financial statements for the financial period ending on 31 December 2023 on 13 March 2024. 

To provide its investors with comparative information already before the publication of the financial statements and financial statements release, Aiforia has prepared the following unaudited financial information following the IFRS standard:

• Income statements for the comparison periods 1 January to 31 December 2022, 1 January to 30 June 2022, 1 July to 31 December 2022 and 1 January to 30 June 2023
• Balance sheets from the time of transition on 1 January 2022 and 31 December 2022 as well as from the reporting periods ending on 30 June 2022 and 30 June 2023

The above-mentioned information as well as the effects of the IFRS transition and the key differences to Finnish accounting standards are described in the appendix to this release.

This company release is a summary of Aiforia's transition to IFRS reporting and unaudited comparative IFRS information. The complete information is attached to this announcement and available at https://investors.aiforia.com/en/.

Further inquiries

Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358405009878
https://investors.aiforia.com/ 

Certified Adviser

UB Corporate Finance Oy
ubs@unitedbankers.fi  

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.

Find out more at www.aiforia.com